Michael Mullan is a biomedical researcher whose research on Alzheimer’s disease is well known among the biomedical community. Dr. Mullan’s work resulted in identifying the first mutation that results in familial Alzheimer’s Disease, the Swedish mutation. In addition to contributing insight into the role of Amyloid Beta in Alzheimer’s Disease, the Swedish mutation is also widely used to develop transgenic animal models of Alzheimer Disease that are crucial for biomedical research.
Dr. Mullan is currently the director of the Roskamp Institute in Sarasota, Florida. Under Dr. Mullan’s guidelines the institute is carrying out cutting edge research on Alzheimer’s, Traumatic Brain Injury, Gulf War Illness, and other neuropsychiatric disorders.
The Roskamp Institute is devoted to understanding causes of and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. Based in Sarasota, Florida, the Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease.
Headed by Dr. Michael Mullan, the institute employs experienced and interdisciplinary scientists and technicians and houses state-of-the-art research labs and equipment to conduct scientific research. The quality of research performed at the institute reflects its motto: “Better science. Real discovery.”
Please visit websites to learn about Dr. Mullan Alzheimer’s Research Website: